Melanoma and Immunotherapy
Hematology / Oncology Clinics of North America , Volume 23 - Issue 3 p. 547- 564
About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.
|4 1bb antibody, Antibodies, CD4 antibody, Cytokines, Immunotherapy, Melanoma, Review, Vaccines, adoptive immunotherapy, antibody, as 02b, as 15, bms 663513, cancer adjuvant therapy, cancer chemotherapy, cancer combination chemotherapy, cancer gene therapy, cancer immunization, cancer immunotherapy, cancer radiotherapy, cancer vaccine, canvaxin, carmustine, cd137 antibody, cisplatin, clinical trial, cnto 95, cytotoxic T lymphocyte antigen 4 antibody, dacarbazine, dendritic cell vaccine, drug bioavailability, drug megadose, fatigue, gene transfer, glycoprotein gp 100, histamine, human, immunological adjuvant, ipilimumab, low drug dose, melacine, melanoma, melanoma antigen 3, metastasis, neutropenia, nonhuman, peginterferon alpha, priority journal, recombinant alpha interferon, recombinant interleukin 15, recombinant interleukin 2, recombinant interleukin 21, recombinant protein, review, tamoxifen, temozolomide, tg 1024, ticilimumab, transaminitis, unclassified drug, unindexed drug, unspecified side effect, vinblastine, vitespen, volociximab|
|Hematology / Oncology Clinics of North America|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Eggermont, A.M.M, & Schadendorf, D. (2009). Melanoma and Immunotherapy. Hematology / Oncology Clinics of North America (Vol. 23, pp. 547–564). doi:10.1016/j.hoc.2009.03.009